Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions

Evangelia Karvouni; Demosthenes G. Katritsis; John P A Ioannidis

doi:10.1016/s0735-1097(02)02666-9

Related publications

Article2003

Effect of intravenous glycoprotein IIb/IIIa receptor antagonists on survival in percutaneous coronary interventions: A meta-analysis

Evangelia Karvouni, Demosthenes G. Katritsis, John P A Ioannidis

Article2007

Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE)

David Brieger, Frans Van de Werf, Álvaro Avezum, Gilles Montalescot, Brian M. Kennelly, Christopher B. Granger, Shaun G. Goodman, Omar Dabbous, Giancarlo Agnelli

Article2000

Long-Term Treatment with a Platelet Glycoprotein-Receptor Antagonist after Percutaneous Coronary Revascularization

William W. O’Neill, Patrick W. Serruys, M.L. Knudtson, Gerrit‐Anne van Es, GERALD C. TIMMIS, C. van der Zwaan, Jay H. Kleiman, Jianjian Gong, Ellen B. Roecker, Roger J. Dreiling, John C. Alexander, Robert J. Anders

New England Journal of Medicine

Article2007

Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes

Omar Dabbous, Frederick A. Anderson, Joel M. Gore, Kim A. Eagle, Keith A.A. Fox, Rajendra H. Mehta, Robert J. Goldberg, Giancarlo Agnelli, Philippe Gabríel Steg

Article2006

Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups

Adrían V. Hernández, Cynthia M. Westerhout, Ewout W. Steyerberg, John P A Ioannidis, Héctor Bueno, H. D. White, Pierre Théroux, David J. Moliterno, Paul W. Armstrong, Robert M. Califf, Lars Wallentin, M. L. Simoons, Eric Boersma